Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01847586
Other study ID # 215/2012
Secondary ID
Status Completed
Phase N/A
First received April 26, 2013
Last updated January 22, 2018
Start date April 2013
Est. completion date October 2017

Study information

Verified date January 2018
Source Centre for Addiction and Mental Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if a novel brain stimulation approach using magnetic stimulation (Transcranial Magnetic Stimulation [TMS]) can improve memory and thinking processes in individuals with mild Alzheimer's disease (AD).


Description:

In this study, the investigators aim at assessing and then enhancing neuroplasticity in the dorsolateral prefrontal cortex (DLPFC) and working memory - a key function of DLPFC - in patients with mild AD. The investigators will use a novel non-invasive brain stimulation approach, Paired Associative Stimulation (PAS). PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.

Specific Aim 1: To compare LTP in the DLPFC among patients with mild AD and healthy subjects.

Specific Aim 2: To assess the effect of a 2-week course of PAS (rPAS) as applied to the left DLPFC on LTP and performance on working memory in patients with mild AD in comparison with a 2-week course of PAS control condition (PAS-C, described below) (rPAS-C).


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date October 2017
Est. primary completion date October 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria for patients:

- Age 65 or above

- Meet NINCDS-ADRDA and DSM-IV TR criteria for a current diagnosis of Alzheimer's Disease

- Stable does of acetylcholinesterase inhibitors for at least 3 months

- Willingness and ability to speak English

- Willingness and ability to provide informed consent

- Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice.

Exclusion Criteria for patients:

- Meets criteria for an Axis I diagnosis within the past 12 months other than Dementia of the Alzheimer type.

- Mini Mental Status Examination score of 16 or less as described above

- Meets diagnostic criteria for current alcohol or other drug dependence within 6 months of testing

- Electroconvulsive Therapy (ECT) within 6 months of testing.

- Left handedness.

- Incompetency to consent

- Any contraindication for TMS

Inclusion Criteria for healthy controls:

- Age 65 or above

- Willingness and ability to speak English

- Willingness and ability to provide informed consent

- Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice.

Exclusion Criteria for healthy controls:

- Meets criteria for an Axis I diagnosis other than simple phobias or adjustment disorder.

- Other neurological disorder affecting central nervous system.

- Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks.

- Left handedness

- Any contraindication for TMS

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Paired Associative Stimulation
PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
Paired Associative Stimulation-Control
PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Paired Associated Stimulation induced Long-term potentiation as a measure of neuroplasticity in the dorsolateral prefrontal cortex We are using a novel technique of TMS- EEG as developed by our group. Through this technique, not only motor evoked potential (MEP) but also cortical evoked activity (CEA) is recorded continuously while TMS is being delivered to the cortex. Thus, PAS-induced LTP could be indexed through the potentiation of not only MEP but also of CEA. TMS-EEG has been used by our group and others. Our group has used TMS-EEG in healthy individuals and patients with severe mental illness to study several neurophysiological phenomena in M1 and DLPFC such as cortical inhibition, gamma oscillations, and recently LTP.
In summary, we propose to combine PAS with TMS-EEG to assess DLPFC neuroplasticity in patients with mild AD and then deliver a 2-week course of daily repetitive PAS (rPAS) to enhance DLPFC neuroplasticity and function as indexed by the N-back task. This will be measured to see if there are any changes after 1 day, 7 days and 14 days of the intervention procedure.
14 days
Secondary N-back Task Working Memory Assessment: Participants will have their working memory assessed pre- and 1, 7, and 14 days post intervention using the N-back task. In the N-back task participants determine whether a stimulus is the same as that presented N trials back. One and 7 days post-intervention, the N-back task will be administered to assess the short- and long-term effect of rPAS on working memory as our preliminary data demonstrate a long-term enhancing effect of PAS on motor learning pre-intervention (baseline) and then 1, 7, 14 days after intervention
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3